

# KAPPAC PHARMA LIMITED

CIN:L24230MH1981PLC025002

Tel No: 022-26735554 E mail: [kappacpharma@yahoo.com](mailto:kappacpharma@yahoo.com)

Date: 03.11.2018

To,  
Listing Department,  
BSE Limited,  
P J Tower, Dalal Street  
Mumbai-400001  
Scrip Code: 506938

Dear Sir/Madam,

Sub: Submission of Audited Financial Result for Quarter and Half-Year ended September 30, 2018 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015


In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone) of the Company for the Quarter and Half-Year ended September 30, 2018 were approved by the Board of Directors of the Company at its meeting held today.

Pursuant to the applicable provisions of the Listing Regulations, we enclose the following:

1. The Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half-Year ended September 30, 2018;
2. Limited Review Reports on the Unaudited Financial Results (Standalone) for the said quarter.

We request you to take the same on records.

Yours Faithfully,  
For, KAPPAC PHARMA LIMITED

  
(ARUN VAGHASIYA)  
DIRECTOR  
DIN: 02420886

# KAPPAC PHARMA LTD.

CIN:- L24230MH1981PLC025002

Regd. Office: 3/204, Mahajbeen Arched, Plot No. H-61, New Link Road, Opp Ashiwara Police Stn., Andheri (West), Mumbai - 400053

Email - kappacpharma@yahoo.com

## Statement of Audited Financial Results for the Quarter & Half Year Ended September 30, 2018

| Sl no.    | Particulars  | Quarter Ended   |                 |                 | Six Months Ended |                 | (Rs. In lacs)          |
|-----------|--|-----------------|-----------------|-----------------|------------------|-----------------|------------------------|
|           |  | 30-Sep-18       | 30-Jun-18       | 30-Sep-17       | 30-Sep-18        | 30-Sep-17       | Year Ended 31 Mar 2018 |
|           | (Refer Notes Below)  | (Unaudited)     | (Unaudited)     | (Unaudited)     | (Unaudited)      | (Unaudited)     | (Audited)              |
| <b>1</b>  | <b>INCOME</b>  |                 |                 |                 |                  |                 |                        |
| (a)       | Revenue From Operation   | -               | -               | -               | -                | -               | -                      |
| (b)       | Other Income   | -               | -               | -               | -                | -               | -                      |
|           | <b>Total Income from Operations (Net)</b>  | -               | -               | -               | -                | -               | -                      |
| <b>2</b>  | <b>EXPENSES</b>  |                 |                 |                 |                  |                 |                        |
| (a)       | Cost of material consumed  | -               | -               | -               | -                | -               | -                      |
| (b)       | Purchase of stock in trade   | -               | -               | -               | -                | -               | -                      |
| (c)       | Changes in inventories of finished goods, work-in-progress, and stock-in-trade   | -               | -               | -               | -                | -               | -                      |
| (d)       | Employee benefit expense   | -               | -               | -               | -                | -               | -                      |
| (e)       | Depreciation and amortization expense  | -               | -               | -               | -                | -               | -                      |
| (f)       | Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately) | 0.20            | 0.12            | 0.20            | 0.32             | 0.46            | 0.69                   |
|           | <b>Total Expenses</b>  | <b>0.20</b>     | <b>0.12</b>     | <b>0.20</b>     | <b>0.32</b>      | <b>0.46</b>     | <b>0.69</b>            |
| <b>3</b>  | <b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>                  | <b>(0.20)</b>   | <b>(0.12)</b>   | <b>(0.20)</b>   | <b>(0.32)</b>    | <b>(0.46)</b>   | <b>(0.69)</b>          |
| 4         | Other Income   | -               | -               | -               | -                | -               | -                      |
| <b>5</b>  | <b>Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)</b>                     | <b>(0.20)</b>   | <b>(0.12)</b>   | <b>(0.20)</b>   | <b>(0.32)</b>    | <b>(0.46)</b>   | <b>(0.69)</b>          |
| 6         | Finance Costs  | -               | -               | -               | -                | -               | -                      |
| <b>7</b>  | <b>Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)</b>               | <b>(0.20)</b>   | <b>(0.12)</b>   | <b>(0.20)</b>   | <b>(0.32)</b>    | <b>(0.46)</b>   | <b>(0.69)</b>          |
| 8         | Exceptional Items  | -               | -               | -               | -                | -               | -                      |
| <b>9</b>  | <b>Profit / (Loss) from ordinary activities before tax (7 ± 8)</b>   | <b>(0.20)</b>   | <b>(0.12)</b>   | <b>(0.20)</b>   | <b>(0.32)</b>    | <b>(0.46)</b>   | <b>(0.69)</b>          |
| 10        | Tax Expense  | -               | -               | -               | -                | -               | -                      |
| <b>11</b> | <b>Net Profit / (Loss) from ordinary activities after tax (9 ± 10)</b>   | <b>(0.20)</b>   | <b>(0.12)</b>   | <b>(0.20)</b>   | <b>(0.32)</b>    | <b>(0.46)</b>   | <b>(0.69)</b>          |
| 12        | Extraordinary items (net of tax )  | -               | -               | -               | -                | -               | -                      |
| <b>13</b> | <b>Net Profit / (Loss) for the period (11 ± 12)</b>  | <b>(0.20)</b>   | <b>(0.12)</b>   | <b>(0.20)</b>   | <b>(0.32)</b>    | <b>(0.46)</b>   | <b>(0.69)</b>          |
| 14        | Paid-up equity share capital (Face Value of Rs. 10/- each)   | <b>3,026.50</b> | <b>3,026.50</b> | <b>3,026.50</b> | <b>3,026.50</b>  | <b>3,026.50</b> | <b>3,026.50</b>        |
| 15        | Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year                                | -               | -               | -               | -                | -               | 769.28                 |
| 16.i      | <b>Earnings Per Share (before extraordinary items) (of Rs. 10/- each) (not annualised):</b>                            |                 |                 |                 |                  |                 |                        |
|           | (a) Basic  | (0.00)          | (0.00)          | (0.00)          | (0.00)           | (0.00)          | (0.00)                 |
|           | (b) Diluted  | (0.00)          | (0.00)          | (0.00)          | (0.00)           | (0.00)          | (0.00)                 |
| 16.ii     | <b>Earnings Per Share (after extraordinary items) (of Rs. 10/- each) (not annualised):</b>                             |                 |                 |                 |                  |                 |                        |
|           | (a) Basic  | (0.00)          | (0.00)          | (0.00)          | (0.00)           | (0.00)          | (0.00)                 |
|           | (b) Diluted  | (0.00)          | (0.00)          | (0.00)          | (0.00)           | (0.00)          | (0.00)                 |



# KAPPAC PHARMA LTD.

CIN:- L24230MH1981PLC025002

Regd. Office: 3/204, Mahajbeen Arched, Plot No. H-61, New Link Road, Opp Ashiwara Police Stn., Andheri (West), Mumbai - 400053

Email:- kappacpharma@yahoo.com

(Rs. in Lakhs)

| Standalone Statement of Assets and Liabilities |  | As at 30th September, 2018 | As at 31st March, 2018 |
|--|--|----------------------------|------------------------|
| Particulars                                    |  | Un-Audited                 | Audited                |
| <b>A</b>                                       | <b>ASSETS</b>  |                            |                        |
| <b>1</b>                                       | <b>Non-current assets</b>                                  |                            |                        |
|  | Property, plant and equipment                              | -                          | -                      |
|  | Capital work-in-progress                                   | -                          | -                      |
|  | Other intangible assets                                    | -                          | -                      |
|  | Investments in subsidiaries, associates and joint ventures | -                          | -                      |
|  | <b>Financial assets</b>                                    |                            |                        |
|  | Investments  | 3,799.06                   | 3,799.06               |
|  | Loans  | -                          | -                      |
|  | Other financial assets                                     | -                          | -                      |
|  | Income Tax assets (net)                                    | -                          | -                      |
|  | Deferred tax assets (net)                                  | -                          | -                      |
|  | Other non-current assets                                   | -                          | -                      |
|  | <b>Sub-total - Non-Current Assets</b>                      | <b>3,799.06</b>            | <b>3,799.06</b>        |
| <b>2</b>                                       | <b>Current assets</b>                                      |                            |                        |
|  | Inventories  | -                          | -                      |
|  | <b>Financial assets</b>                                    |                            |                        |
|  | Investments  | -                          | -                      |
|  | Trade receivables  | -                          | -                      |
|  | Cash and cash equivalents                                  | 0.98                       | 1.30                   |
|  | Bank balances other than Cash and Cash equivalents above   | -                          | -                      |
|  | Loans, Current   | -                          | -                      |
|  | Other financial assets                                     | 19.18                      | 19.18                  |
|  | Other current assets                                       | 1.55                       | 1.55                   |
|  | Assets classified as held for sale                         | -                          | -                      |
|  | <b>Sub-total - Current Assets</b>                          | <b>21.71</b>               | <b>22.03</b>           |
|  | <b>TOTAL - ASSETS</b>                                      | <b>3,820.77</b>            | <b>3,821.09</b>        |
| <b>B</b>                                       | <b>EQUITY AND LIABILITIES</b>                              |                            |                        |
| <b>1</b>                                       | <b>Equity</b>  |                            |                        |
|  | Equity Share capital                                       | 3,026.50                   | 3,026.50               |
|  | Other equity   | 768.96                     | 769.28                 |
|  | <b>Sub-total - Shareholders' funds</b>                     | <b>3,795.46</b>            | <b>3,795.78</b>        |
| <b>2</b>                                       | <b>LIABILITIES</b>   |                            |                        |
|  | <b>Non-current liabilities</b>                             |                            |                        |
|  | <b>Financial liabilities</b>                               |                            |                        |
|  | Borrowings, non-Current                                    | -                          | -                      |
|  | Provisions   | -                          | -                      |
|  | Income tax liabilities (net)                               | -                          | -                      |
|  | Other non-current liabilities                              | -                          | -                      |
|  | <b>Sub-total - Non-current liabilities</b>                 | <b>-</b>                   | <b>-</b>               |
| <b>3</b>                                       | <b>Current liabilities</b>                                 |                            |                        |
|  | <b>Financial liabilities</b>                               |                            |                        |
|  | Borrowings, Current  | 20.00                      | 20.00                  |
|  | Trade payables, Current                                    | -                          | -                      |
|  | Other financial liabilities                                | -                          | -                      |
|  | Other current liabilities                                  | 5.31                       | 5.31                   |
|  | Provisions   | -                          | -                      |
|  | Current tax liabilities (net)                              | -                          | -                      |
|  | <b>Sub-total - Current liabilities</b>                     | <b>25.31</b>               | <b>25.31</b>           |
|  | <b>TOTAL - EQUITY AND LIABILITIES</b>                      | <b>3,820.77</b>            | <b>3,821.09</b>        |





# KAPPAC PHARMA LTD.

CIN:- L24230MH1981PLC025002

Regd. Office: 3/204, Mahajbeen Archd, Plot No. H-61, New Link Road, Opp Ashiwara Police Strn., Andheri (West), Mumbai - 400053

Email:- kappacpharma@yahoo.com

## Notes:

- 1 The format of Quarterly results are prescribed in SEBI circular Ref. CIR/CFD/FAC/62/2016 dated July 05, 2016 has been modified to comply with requirements of SEBI's circular dated 5th July, 2016, Ind - AS and Schedule III (Division II) of Companies Act, 2013 applicable to companies that are required to comply with IND-AS.
- 2 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 03, 2018. The Statutory Auditors have carried out a limited review of the above financial result.
- 3 Company has only one segment and hence no separate segment result has been given.
- 4 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- 5 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

By order of the Board  
For KAPPAC PHARMA LTD.



Director/Compliance Officer

Place : Ahmedabad

Date : 03rd November, 2018